Tags |
|
|
Main Subject - Some Innovative Thoughts On Consumer Loyalty
So where are your consumers?
Are they faster than we are in learnin
Are they faster than we are in learnin
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
g and utilizing all the new features technology has to offer than we
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
are marketers are? Are we on the other hand as consumers (because e
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
ach of us is a consumer as well, even though some times we might for
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
et it) doing the same thing we are fast to adopt new technology fo
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
r our own consumption, but when it comes down to utilizing it as mar
ucts have become life saving products for the pharmaceutical companies who doesnt have many innovative molecules in their product pipeline and have been inc
keters to plan there, to understand it from an advertisers point o
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
view we tend to stick to the traditional marketing tools and why?
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
And yes, each of us has one thousand thing to do throughout the day
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
in terms of projects and planning and responses and sometimes time i
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
just not enough. But then it all comes down to how efficient we are
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
. Because yes the traditional marketing tools are known and we are u
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
sed to implementing them and we implement them fast. But then the qu
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
estion is are we efficient? Are we reaching our consumers as we di
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
before? Are we talking to them though the media they actually consu
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
me or have they already moved away to other ones and we are talkin
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
g in front of a sparse audience? Because if this is the case how a
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
e we to build their loyalty? How many have left? And then probably o
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
ne of the scariest questions where is our competition have they
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
moved ahead and are they encountering our consumers where we are not
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.mainsubjects.org.ua/article/25102/mainsubjects-Some-Innovative-Thoughts-On-Consumer-Loyalty.html">Some Innovative Thoughts On Consumer Loyalty</a>
BB link (for phorums):
[url=http://www.mainsubjects.org.ua/article/25102/mainsubjects-Some-Innovative-Thoughts-On-Consumer-Loyalty.html]Some Innovative Thoughts On Consumer Loyalty[/url]
Related Articles:
Generating Great Business Ideas
Color Documents: Which Color Type Is Best?
35 Ways To Tune-Up Your Creativity
Bookmark it:
|